Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients

Table 2

Adverse events during the PPV ().

Event	Number
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total (%)
Injection site skin reaction	15	4	2	0	0	21 (50%)
Blood/bone marrow
Anemia	7	4	0	0	0	11 (26%)
Lymphopenia	9	1	0	0	0	10 (24%)
Neutropenia	0	2	0	0	0	2 (5%)
Thrombocytopenia	7	0	0	0	0	7 (17%)
Leukopenia	3	1	0	0	0	4 (10%)
Laboratory
AST increase	4	6	4	0	0	14 (33%)
ALT increase	10	1	2	0	0	13 (31%)
ALP increase	9	2	0	0	0	11 (26%)
GGT increase	7	3	2	0	0	12 (29%)
Bilirubin increase	2	2	0	0	0	4 (10%)
Creatinine increase	2	1	0	0	0	3 (7%)
Gastrointestinal disorders
Anorexia	5	3	0	0	0	8 (19%)
Abdominal distension	2	0	0	0	0	2 (5%)
Ascites	2	1	1	0	0	4 (10%)
Constipation	0	2	0	0	0	2 (5%)
Edema limbs	2	0	0	0	0	2 (5%)
Fever	5	0	0	0	0	5 (12%)
Malaise	3	0	0	0	0	3 (7%)
Pain	1	3	2	0	0	6 (14%)
Pruritus	2	0	0	0	0	2 (5%)
Eruption	2	1	0	0	0	3 (7%)
Urinary incontinence	0	1	0	0	0	1 (2%)
Pleural infection	0	0	0	0	1	1 (2%)
Hypertension	0	0	1	0	0	1 (2%)
Insomnia	0	1	0	0	0	1 (2%)